Over the past 12 months, $CMPX has been mentioned 4 times by 2 distinct FinTwit voices, with the first mention appearing on August 13, 2025. Jacob Plieth (@jacobplieth) is the most active voice discussing Compass Therapeutics, accounting for 3 of the 4 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The biotech category dominates discussion of this ticker among the voices tracked.

The most recent activity occurred on April 27, 2026, surrounding Compass Therapeutics' Companion-002 study results for tovecimig. On that date, Jacob Plieth noted that "patient crossover ate my OS benefit," while Adam Feuerstein detailed receiving unverified information from someone claiming to be a Compass employee prior to the official data release, noting that the purported positive PFS and OS data proved entirely false when actual results were reported.